Compare Appian Corp (APPN) vs Centene Corp (CNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Centene Corp — how do they compare? Appian Corp trades at $26.57 (market cap $1.86B), while Centene Corp trades at $68.27 (market cap $33.26B). The key difference: Centene Corp is far larger — about 17.9× Appian Corp's market cap, and Centene Corp is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| APPN | CNC | |
|---|---|---|
Market Cap | $1.86B | $33.26B |
Sector | Technology | Health |
52-Week High | $45.64 | $68.34 |
52-Week Low | $18.72 | $25.21 |
Enterprise Value | $1.95B | $25.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $25.36, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus price target of $26.20. The company reported positive net income in 2025 after years of losses, with revenue growing to $726.94M and operating cash flow improving to $62.87M. Recent news highlights focus on AI strategy and enterprise adoption, though the CEO's share sale and negative shareholder equity present mixed signals.
The outlook is cautiously optimistic with revenue growth and cash flow recovery, but risks include high debt levels, negative equity, and intense competition. Analyst sentiment is mixed with a majority Hold rating. The stock offers potential from AI-driven growth but requires monitoring of profitability sustainability and balance sheet health.
Centene (CNC) trades at $67.35, down 0.37% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation ratios, including a P/E of 8.06 and P/S of 0.17, but faces profitability challenges with a negative net income margin of -3.25% for 2025. Recent positive developments include the renewal of a key Illinois Medicaid contract and consistent earnings beats in recent quarters, supporting a strong analyst consensus with 61% buy ratings.
The outlook for CNC hinges on successful margin recovery initiatives and cost management. Investment opportunities lie in its undervalued metrics and stable revenue base, but risks include persistent negative profitability, regulatory pressures in healthcare, and execution challenges in improving medical cost controls. The consensus price target of $63.36 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →
